Personalized cell therapy for advanced lung cancer shows early promise but trial halted
NCT ID NCT06491225
First seen May 06, 2026 · Last updated May 22, 2026 · Updated 3 times
Summary
This early-stage study tested a new treatment called GTE-001, which uses immune cells taken from a patient's own tumor to attack advanced lung adenocarcinoma. The trial was open to adults whose cancer had returned after standard chemotherapy. Only 2 people enrolled before the study was stopped early, so results are very limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LUNG ADENOCARCINOMA；ADULT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing GoBroad Hospital
Beijing, Beijing Municipality, 102200, China
Conditions
Explore the condition pages connected to this study.